Purpose : Compare the efficacy and safety of two different GnRHa, used for pituitary suppression in IVF cycles. Methods: A total of 292 patients using depot goserelin (Group 1) and 167 using daily leuprolide acetate (Group 2) were compared. Days required to achieve pituitary function suppression, duration of ovarian stimulation, total dose of HMG, number of aspirated follicles, number of oocytes retrieved, and presence of functional ovarian cyst were analyzed. Results: The time taken to achieve downregulation was similar. The mean number of ampoules used for superovulation was higher in Group 1; however, this difference was observed only for patients >40 years old that started GnRHa in the follicular phase. There was no difference between the two groups in the duration of superovulation, in the number of follicles aspirated, and the number of oocytes retrieved. In the group of patients with >40 years the incidence of ovarian cysts was higher in Group 2. Conclusions: Both routes of GnRHa have similar effects for pituitary suppression and ovulation induction in assisted reproductive technology. Therefore the long-acting GnRHa is an excellent option, as only a single subcutaneous dose is necessary, decreasing the risk of the patient to forget its use and, most important, it does not interfere in the patient's quality of life.
INTRODUCTION
One of the most important advances in the field of assisted reproductive technologies was the development of the gonadotrophin-releasing hormone analogues (GnRHa) (1) . The GnRHa are used in combination with menotropins or recombinant FSH (follicle-stimulating hormone) to induce folliculogenesis for controlled ovarian hyperstimulation in women undergoing in vitro fertilization (IVF). The benefits from the use of the GnRHa in assisted reproductive methods derive principally from the absence or reduction in the incidence of premature luteinizing hormone (LH) surge and premature luteinization (2-4). Therefore, the incidence of cycle cancellation has decreased, and the incidence of embryo transfer per cycle started has increased (5, 6) . The possibility to avoid LH surge also improved patient and physician convenience, allowing oocyte retrieval to be performed only on week days (7) . Moreover, lower concentrations of bioactive LH also decrease local ovarian androgen concentrations, enhancing estrogen/androgen ratio and improving the oocyte performance (8) .
The other positive effects of the GnRHa are the increasing in the number and synchronization of developing follicles (9, 10) , increasing in the average number of oocytes obtained at retrieval (11) , augmentation of oocyte maturation synchrony, and most important, its use has raised pregnancy rates in IVF treatment when compared with cycles not using GnRHa (12) .
Many protocols that combine GnRHa and gonadotrophins have been proposed within the last years; however, the long protocol have been the most widely used because of its better results (13, 14) . The long protocol aims to obtain pituitary suppression before ovulation induction. The GnRHa is started either in the early follicular phase or in the midluteal phase of the previous cycle and must be continued at least until the induction of oocyte maturation. The other advantage of this regimen is the possibility to schedule patients for treatment.
Several GnRHa with different chemical structure and formulation, biological potencies, serum half-life, dosing requirement, and various routes of administration have been developed. The selection of one specific agent for use in IVF treatment depends mostly on its benefits for the treatment, i.e., good results in obtaining downregulation, high number of developing follicles and oocytes retrieved. It is also important that the chosen GnRHa does not increase the length and the costs of treatment. Moreover, the clinician experience with the analogue and the impact of the route of administration on the patients' quality of life are also fundamental to obtain good treatment results.
Although many studies have been performed to find out whether one compound was better than the others, no data suggested clinical superiority of any GnRHa (15, 16) . The aim of our prospective randomized study was to compare the efficacy and safety of two different GnRHa with different route of administration, used for pituitary suppression in IVF cycles using the same protocol.
MATERIAL AND METHODS
A total of 459 patients referred for IVF treatment at the ORIGEN, Centro de Medicina Reprodutiva, were included in this prospective study, performed between October 1995 and March 1998. Patients were randomized to receive either one dose of subcutaneous goserelin (Zoladex, Zeneca, Brazil) or subcutaneous daily leuprolide acetate (Lupron, Abbot, Brazil), according to the phase of the year they started treatment, i.e., starting first semester used goserelin and 2nd semester used leuprolide. All patients that used the appropriate GnRHa were included in the study. The decision of starting on the follicular or luteal phase was made by the patients according to their own comfort. This study was approved by our institutional ethics committee according to the code of ethics of the Conselho Federal de Medicina (Brazilian National Medical Council).
Patients
A total of 292 patients (63.6%) used goserelin (Group 1), and 167 (36.4%) used leuprolide acetate (Group 2). All patients had long protocol for pituitary suppression and the same stimulation protocol for ovulation induction regardless of the type of GnRHa used. The groups were comparable in indications for IVF and age ( p > 0.05). Indications for IVF were male factor, tubal disease, endometriosis, and unexplained infertility.
Stimulation Protocol
Treatment started on Day 2 (follicular phase) or Day 21 (luteal phase) of the menstrual cycle with GnRHa. Patients of Group 1 received subcutaneous administration of 3.6 mg of goserelin (Zoladex, Zeneca, Brazil) and of Group 2 started daily subcutaneous administration of 1 mg of leuprolide acetate (Lupron, Abbot, Brazil) for suppression of the pituitary function. To confirm pituitary suppression, serum estradiol (E 2 ) levels and vaginal ultrasound were performed 7-10 days later (according to patient's convenience). If the E 2 concentration was less than 30 pg/mL and the ultrasound showed an endometrial thickness of less than 3 mm, patients were considered ready to start ovulation induction. If patients were not ready, serum E 2 and vaginal ultrasound were repeated every other day until suppression was achieved.
After confirmation of suppression, all patients were superovulated with daily human menopausal gonadotrophin (HMG; 75 IU of FSH/LH per ampoule) intramuscular injections. The starting dose of HMG was defined according to patient's age, and the dose was tailored according to the E 2 levels and follicular growth monitored by vaginal ultrasound (Tosbee, Toshiba, Japan). Human chorionic gonadotrophin (hCG; 10000 IU) was given when at least two follicles reached a mean size of 17 mm with concordant estradiol levels. Oocyte retrieval was performed ∼34 h after hCG injection by vaginal ultrasound guided aspiration. IVF or intracytoplasmic sperm injection procedure were performed as previously described (17) .
Cysts Aspiration
The presence of a functional ovarian cyst was considered when observed at ultrasound and associated with elevated E 2 levels when patients were examined to confirm downregulation. If pituitary function suppression was not achieved within 15 days, ovarian cysts were aspirated by vaginal ultrasound guided suction.
Statistical Analysis
Statistical analysis to compare the two groups was performed using the Kruskal-Wallis test for the following criteria evaluated: days required to achieve pituitary function suppression, duration of ovarian stimulation, total dose of HMG (number of ampoules), number of aspirated follicles, number of oocytes retrieved. To compare the presence of functional ovarian cyst, age of patients and menstrual cycle phase to start GnRHa, between the two groups, chisquare test and Fisher's exact test were performed. A difference was considered significant when p < 0.05.
RESULTS
The mean ± SD age in Group 1 was 34.4 ± 4.7 (range 23-44 years) and 34.3 ± 5.4 (range 20-44 years) in Group 2 (not significantly different). Downregulation was achieved in all patients in both groups before superovulation. In Group 1, 78.3% of the patients started GnRHa on the follicular phase, and in Group 2, 80.6% (not significant). All cycles included in the study reached the criteria for oocyte retrieval.
In both groups, the time taken to achieve downregulation was similar: 14.2 ± 5.5 days for Group 1 (range 8-60) and 13.8 ± 6.3 days for Group 2 (range 7-35). However for the patients that started treatment in the follicular phase and for the patients with ≤30 years, the time was statistically significantly longer in Group 1 ( Table I) .
The mean number of ampoules used for superovulation was statistically higher in Group 1 (range 12-118 in Group 1 and 13-91 in Group 2). However, this difference was observed only for patients that started GnRHa in the follicular phase, and in the group of patients >40 years old (Table II) . The mean ± SD number of days of HMG taken to reach criteria for hCG administration was 11.9 ± 5.3 days in Group 1 (range 8-18) and 11.6 ± 3.4 days in Group 2 (range 7-17). There was no difference between the two groups if the patients started GnRHa in the follicular or luteal phase. The duration of superovulation was also not statistically different between the two groups, when considered by age groups (Table III) .
There was no significant difference between the two groups in the number of follicles aspirated and the number of oocytes retrieved. In the goserelin group, a mean number of 11.2 follicles were punctured (range 2-33), and 12.8 oocytes were retrieved (range 0-52). In the leuprolide acetate group, a mean number of 13.6 follicles were punctured (range 2-76) and 12.4 oocytes were retrieved (range 0-78). These numbers were also not different whether the patients started GnRHa in the follicular or luteal phase or according to age group (Table III) .
The presence of ovarian cysts was observed in 56 patients in Group 1 (19.2%) and in 39 patients in Group 2 (23.5%). The difference was not significant between the two groups. There was also no difference between the two groups if the patients started GnRHa in the follicular or luteal phase. However in the group of patients with >40 years, the incidence of ovarian cysts was statistically higher in Group 2 (Table IV) . All ovarian functional cysts were aspirated, and no complications were recorded.
DISCUSSION
Our study evaluates two different GnRHa with different formulation and routes of administration. Some studies have previously demonstrated the efficacy of one dose of subcutaneous goserelin (15, 16, 18, 19) for pituitary suppression, before ovarian hyperstimulation in women undergoing IVF; however, only a small number of patients have been evaluated in a prospective randomized study. Tapanainen et al. (15) evaluated 49 patients that underwent IVF, using goserelin for pituitary suppression, starting at the luteal phase for a long protocol treatment, that were compared to 51 women using buserelin. The only observed difference was a higher number of ampoules needed for follicular maturation in the goserelin group. To our knowledge this is the second prospective randomized study comparing one dose of goserelin to daily administration of GnRHa, the first comparing goserelin to leuprolide acetate and the study with the highest number of patients using goserelin.
We did not include laboratory data, such as fertilization rates, embryo quality, number of transferred embryos, and pregnancy rates, in order to avoid any study bias. As during the study time we have used different culture media preparation, different criteria for intracytoplasmic sperm injection, and different stage for embryo transfer, we decided not to include these results as it might have biased the results. We do understand that pregnancy rates are the most important results in infertility treatment studies; however, the main objective of our study was to analyze the endocrine effects of both preparation in the ovaries.
The choice for the long protocol used for all patients was based on the results observed in the literature showing higher implantation and pregnancy rates (4, 13) . The starting day of the GnRHa was either Day 2 or Day 21 of the menstrual cycle, and downregulation was achieved in all patients before superovulation. Although it has been described that the long protocol initiated in the midluteal phase might be more effective and with a lower incidence of functional ovarian cysts formation (20) , our results do not confirm such data. In fact, we observed that irrespective of the phase patients started GnRHa, the same time was needed to achieve downregulation, in both treatment groups. This lack of difference was also observed for functional cyst formation.
We observed that in the group of patients that used single dose preparation (goserelin), only women ≤30 years and that started at follicular phase needed more time to achieve downregulation. As all patients decided by themselves when to return after starting GnRHa for confirmation of pituitary suppression (7-10 days later, according to patient's convenience), we can assume that those who were in use of daily administration of GnRHa decided to perform their first ultrasound and estradiol earlier (7th day) in order to minimize the use of injections. On the other hand, patients that were not using daily injections for downregulation might have delayed the return to the last day (10th day). This can explain the fact that only this small and selected group of patients has shown this difference, and therefore we believe that this was a casual finding. The results observed by Oyesanya et al. (16) however have demonstrated that patients that used goserelin needed less time to reach downregulation. Porcu et al. (21) did not find any difference in the time to reach desensitization when comparing depot (leuprorelin) and daily (buserelin) GnRHa.
Some authors (22) have described higher follicular recruitment and oocyte retrieval when GnRHa was commenced in the early follicular phase. These results are not in concordance with our data that showed similar number of follicles punctured and oocytes retrieved in both groups, irrespective of the cycle phase patients started GnRHa. Also, there were no differences in the time required for follicular development. These results are similar to those obtained by Tapanainem et al. (15) which compared goserelin to buserelin acetate, and demonstrate no differences in the clinical outcome. The same was observed by Oyesanya et al. (16) and Alvarez et al. (23) .
Our results have demonstrated that patients in the goserelin group needed more ampoules of HMG. This result is similar to the findings observed by Tapanainen et al. (15) ; however, in our study this was observed only in a small group of patients, i.e., >40 years old that used goserelin starting in the follicular phase. Alvarez et al. (23) demonstrated that a long administration of GnRHa has no effect upon ovarian response in IVF cycles.
The presence of functional ovarian cysts was observed in 56 patients in Group 1 (19.2%) and in 39 patients in Group 2 (23.5%). Although the incidence was higher than that observed by Sampaio et al. (24) , it was similar in both groups and did not interfere in the treatment as all cysts were drained and no complications were related to the procedure. We observed a higher incidence of functional ovarian cysts in the group of patients >40 years old using leuprolide acetate. This result is not in agreement with Tarlatzis et al. (25) that studying three groups of patients concluded that cyst formation does not seem to be related to the use of a specific GnRHa, its short-or long-acting form, or the mode of administration. Their study however was performed in a small number of patients (172) that might explain the difference.
In conclusion, our results demonstrate that both routes of GnRHa have similar effects for pituitary suppression and ovulation induction in assisted reproductive treatment. Therefore the long-acting GnRHa is an excellent option, as only a single subcutaneous dose is necessary, decreasing the risk of the patient to forget its use and therefore interfere with the downregulation and, most important, it does not interfere in the patient's quality of life. For patients >40 years old it might be suggested another alternative to avoid the increased risk of cyst formation or of needing more ampoules.
